“The Euvichol Story – Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships” spearheaded by the International Vaccine Institute (IVI), has been published in Vaccine by Elsevier.
The Euvichol Story published on October 9, 2018 in the journal Vaccine describes IVI’s efforts and public-private partnerships with collaborators in Sweden, Vietnam, India, South Korea and the U.S. to increase the supply of affordable oral cholera vaccines; as well as IVI’s collaboration with many other stakeholders to shape the demand of affordable OCVs globally.
Within the context of IVI’s partnership with the small South Korean company Eubiologics, this manuscript explores the important role of product development partnerships (PDPs) in facilitating the development and production of a vaccine for a neglected disease like cholera, along with essential support from public and private funding sources.
Developing and delivering vaccines for diseases mainly affecting people in developing countries is a challenging task due to the high costs and risks of vaccine R&D. By mobilizing resources and political will, creating commercial incentives, and building public- and private-sector partnerships, IVI’s synergistic work with partners helped remove several of the obstacles limiting vaccine development, production and introduction for this neglected disease.
IVI’s Cholera Vaccine Program, a philanthropic-funded, public-private partnership overcame the typical obstacles and brought to market affordable, safe, effective and easier-to-deliver vaccines against a neglected disease. However, in addition to generating a vaccine supply, multi-stakeholder engagement was necessary to generate essential evidence on the burden of disease, feasibility, and effectiveness and acceptability of use in multiple settings in order to create demand, conduct advocacy, and shape policy.
The full manuscript in Vaccine, published by Elsevier, can be accessed here: https://www.sciencedirect.com/science/article/pii/S0264410X18312763
“The Euvichol story – Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships,” by Dr. Lina Odevall, Dr. Julia Lynch, and others, DOI: https://doi.org/10.1016/j.vaccine.2018.09.026 It appears in Vaccine Volume 36, issue 45, pp. 6606-6614 (October 29, 2018) published by Elsevier.
Copies of this paper are available to credentialed journalists upon request; please contact Elsevier’s Newsroom at: email@example.com or +31 20 485 2719
Vaccine is the pre-eminent journal for those interested in vaccines and vaccination. It is the official journal of The Edward Jenner Society and The Japanese Society for Vaccinology and is published by Elsevier www.elsevier.com/locate/vaccine